- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06334614
iReach: a Rehabilitative Medical Device
iReach: a Novel Medical Device for Early Intervention for Visually Impaired Infants.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Development and clinical validation of a novel multisensory medical device: iReach. This device will be used for the rehabilitation and recovery of spatial and sensorimotor abilities compromised by early visual impairment (i.e., blindness or moderate to severe low vision) in children aged between 3 and 36 months. In addition to its clinical value, the investigators aim to fill a technological and methodological gap. Currently, there are no certified medical devices for early intervention, that is, systems that are intuitive, simple, and designed for rehabilitation in the early stages of development.
In detail, the goals of the current clinical trial are:
- To verify that the number of adverse events is zero, considering reports from the attending physician;
- To assess improvements in stationary and locomotion abilities, assessed with the Peabody Developmental Motor Scale (PDMS-2) indices;
- To evaluate further improvements in i) reaction time (s) and frequency and accuracy of response (%) to uni- and multisensory (audio-tactile) stimulations; ii) time to reach and grasp an object (s); iii) number of attempts required to reach and grasp an object (%); iv) number of times the midline of the body is crossed to reach a lateral object (%); v) number of times an object is grasped with two hands if it is larger than the hand (%). These parameters will be extracted from video recordings;
- To highlight changes in EEG power (dB) in the alpha band (8-12 Hz) measured in the occipital scalp area following rehabilitation with iReach.
iReach, is composed of two devices called Anchors, and a reference Tag, that can be placed either on both the body or external objects. Each Anchor measures its distance from the Tag and translates it into sensory feedback, whose intensity and time duration parameters are configurable. iReach can emit acoustic, vibrational, and RGB light stimuli, either alone or in combination, and is turned on via a button located on the external cover, which is manufactured through 3D printing.
This study is divided into two phases: usability and rehabilitation. The usability phase is aimed at defining the temporal durations of audio-tactile stimulations that will then be used in the rehabilitation phase. The patients enrolled in the iReach Device group of this phase will be involved in a one-month rehabilitation procedure (i.e., training) and will perform activities with iReach presented in the form of games that target localization, locomotion, grasping, and reaching skills. The training will be conducted both at home and at the clinical center and will be preceded and followed by two identical experimental sessions (pre- and post-training), which will monitor improvements in spatial and sensorimotor abilities following rehabilitation. Finally, an additional follow-up experimental session is planned four months after the post-training to verify whether these improvements are still present or not, both behaviorally and cortically. The participants enrolled in the Normal clinical activity group of the experimental phase will only be involved in the pre- and post-training sessions and the follow-up session without undergoing rehabilitation with iReach. The tasks the participants will have to undergo are designed for the specific age bin (i.e., 3-6 months, 6-12 months, 12-36 months)
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Walter Setti, PhD
- Phone Number: + 393396618515
- Email: walter.setti@iit.it
Study Contact Backup
- Name: Monica Gori, PhD
- Phone Number: + 393601021020
- Email: monica.gori@iit.it
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Obtaining Informed Consent;
- Age between 3 and 36 months;
- Normal vision or visual acuity between 0 and 4.7 cy/deg, assessed using the Teller Acuity Cards;
- Absence of concurrent therapies during the experimentation;
- Adequate cognitive ability for their age, assessed using the Reynell-Zinkin, Bayley III, and/or Griffiths scales;
Exclusion Criteria:
- Children with neurological disorders or cognitive delays (assessed using the Reynell-Zinkin, Bayley III, and/or Griffiths scales);
- Children affected by other sensory disabilities in addition to visual impairment (e.g., deafness) or with motor disorders;
- Premature infants with early gestational age (< 32 weeks);
- Children with diseases affecting the central nervous system or who have experienced epileptic seizures and/or convulsions in the six months before the start of the experimentation;
- Children with tactile hypersensitivity who are taking neuroactive drugs and substances or have taken them in the six months before the start of the experimentation;
- Children with auditory and/or peripheral motor disabilities;
- Children whose parents or legal guardians have not provided informed consent;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: iReach Device group
The iReach Device group will undergo the clinical trial with the device in addition to the normal clinical activity
|
The iReach Device group will take part in playful multisensory motor and spatial activities for one month both at the clinic and at home with the medical device iReach.
|
No Intervention: Normal clinical activity group
The Normal clinical activity group will continue their normal clinical activity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Device Adverse Events
Time Frame: Month 1 - Month 12, the entire duration of the clinical trial
|
Verification of the absence of device adverse events in the use of the medical device (MD);
|
Month 1 - Month 12, the entire duration of the clinical trial
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in motor skills after training with iReach medical device
Time Frame: Month 3 - Month 12
|
The assessment of the change in certain motor skills (e.g., stability, and locomotion) after one month of intensive use of iReach.
These changes will be quantified through the indices of the Peabody Developmental Motor Scales -2 (PDMS-2).
The tasks included in these scales will be adapted to be executable by children with visual impairments.
The PDMS-2 scales are widely used in clinical practice and allow for robust and reliable measurements.
Higher scores result in better outcomes.
The performance values are quantified through an indicator named "Total Motor Quotient," which spans from a minimum range equal to 35-69, representing a strong deficit, to a maximum range of 131-165, indicating the best performance.
|
Month 3 - Month 12
|
Perceptual responses to multisensory stimuli
Time Frame: Month 1 - Month 12
|
Evaluation of the number of correct responses and reaction times (in seconds), to uni- and multisensory (audio-tactile) stimuli.
|
Month 1 - Month 12
|
Change in motor abilities following the rehabilitation with the iReach medical device
Time Frame: Month 1 - Month 12
|
Evaluation of the changes in motor tasks in terms of: i) time to reach and grasp an object (in seconds) ii) number of attempts required to reach and grasp an object; iii) number of times the midline of the body is crossed to reach a lateral object; iv) number of times an object is grasped with two hands when its size exceeds that of the hand.
|
Month 1 - Month 12
|
Variation in the power of the cortical activity following the rehabilitation with the iReach medical device
Time Frame: Month 1 - Month 12
|
Evaluation of the variation in power expressed by the alpha band (8-12 Hz) of the EEG recorded in the occipital area (dB).
|
Month 1 - Month 12
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Campus C, Signorini S, Vitali H, De Giorgis V, Papalia G, Morelli F, Gori M. Sensitive period for the plasticity of alpha activity in humans. Dev Cogn Neurosci. 2021 Jun;49:100965. doi: 10.1016/j.dcn.2021.100965. Epub 2021 May 21.
- Cappagli G, Cocchi E, Gori M. Auditory and proprioceptive spatial impairments in blind children and adults. Dev Sci. 2017 May;20(3). doi: 10.1111/desc.12374. Epub 2015 Nov 27.
- Cappagli G, Finocchietti S, Cocchi E, Giammari G, Zumiani R, Cuppone AV, Baud-Bovy G, Gori M. Audio motor training improves mobility and spatial cognition in visually impaired children. Sci Rep. 2019 Mar 1;9(1):3303. doi: 10.1038/s41598-019-39981-x.
- Finocchietti S, Cappagli G, Ben Porquis L, Baud-Bovy G, Cocchi E, Gori M. Evaluation of the Audio Bracelet for Blind Interaction for improving mobility and spatial cognition in early blind children - A pilot study. Annu Int Conf IEEE Eng Med Biol Soc. 2015 Aug;2015:7998-8001. doi: 10.1109/EMBC.2015.7320248.
- Gori M, Campus C, Signorini S, Rivara E, Bremner AJ. Multisensory spatial perception in visually impaired infants. Curr Biol. 2021 Nov 22;31(22):5093-5101.e5. doi: 10.1016/j.cub.2021.09.011. Epub 2021 Sep 22.
- Setti W, Cuturi LF, Engel I, Picinali L, Gori M. The influence of early visual deprivation on audio-spatial working memory. Neuropsychology. 2022 Jan;36(1):55-63. doi: 10.1037/neu0000776. Epub 2021 Oct 14.
- Vercillo T, Gori M. Attention to sound improves auditory reliability in audio-tactile spatial optimal integration. Front Integr Neurosci. 2015 May 7;9:34. doi: 10.3389/fnint.2015.00034. eCollection 2015.
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIT_iReach
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blindness
-
University of California, Los AngelesActive, not recruiting
-
University Hospital, Clermont-FerrandTerminatedVisual Deficiency | Congenital Blindness | Acquired BlindnessFrance
-
Salgado Institute of Integral HealthCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.UnknownBlindness, Acquired | Blindness CongenitalBrazil
-
Wake Forest University Health SciencesNot yet recruitingHemianopia, Homonymous | Cortical Blindness, Unspecified Side of BrainUnited States
-
Smith-Kettlewell Eye Research InstituteRecruitingBlindness | Low Vision | Blindness, Acquired | Blindness, CompleteUnited States
-
University of the Incarnate WordNational Eye Institute (NEI)CompletedColor Vision Defects | Color Blindness | Color Blindness, Red | Color Blindness, GreenUnited States
-
University of California, Santa BarbaraJohns Hopkins University; University of Michigan; Universidad Miguel Hernandez...Active, not recruiting
-
University of Colorado, DenverCompletedColor Blindness, AcquiredUnited States
-
University of Applied Sciences JenaIGA OPTIC EGCompletedMyopia-Night BlindnessGermany
-
Second Sight Medical ProductsNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruitingBlindness, AcquiredUnited States
Clinical Trials on iReach
-
Ann & Robert H Lurie Children's Hospital of ChicagoNational Institute of Allergy and Infectious Diseases (NIAID)Enrolling by invitationFood Allergy Peanut | Food Allergy in InfantsUnited States
-
Istituto Italiano di TecnologiaEnrolling by invitation